These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 12151865

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA.
    Circulation; 2002 Sep 17; 106(12):1470-6. PubMed ID: 12234950
    [Abstract] [Full Text] [Related]

  • 3. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
    Boersma E, Akkerhuis KM, Théroux P, Califf RM, Topol EJ, Simoons ML.
    Circulation; 1999 Nov 16; 100(20):2045-8. PubMed ID: 10562258
    [Abstract] [Full Text] [Related]

  • 4. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Bhatt DL, Topol EJ.
    JAMA; 2000 Sep 27; 284(12):1549-58. PubMed ID: 11000650
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Optimizing glycoprotein IIb/IIIa inhibition: lessons from recent randomized controlled trials.
    Chew DP, Bhatt DL.
    Intern Med J; 2002 Jul 27; 32(7):338-45. PubMed ID: 12088354
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J, Berent R, Lassnig E, Weber T, Maurer E, Eber B.
    Herz; 2003 Aug 27; 28(5):393-403. PubMed ID: 12928738
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes.
    Tcheng JE.
    Am Heart J; 1999 Oct 27; 138(4 Pt 2):261-2. PubMed ID: 10502231
    [No Abstract] [Full Text] [Related]

  • 12. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions.
    Leclerc JR.
    Crit Care Med; 2002 May 27; 30(5 Suppl):S332-40. PubMed ID: 12004256
    [Abstract] [Full Text] [Related]

  • 13. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
    Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER.
    Circ Cardiovasc Interv; 2009 Jun 27; 2(3):230-6. PubMed ID: 20031720
    [Abstract] [Full Text] [Related]

  • 14. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW, DiBattiste PM, Demopoulos L, TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial.
    N Engl J Med; 2001 Jun 21; 344(25):1888-94. PubMed ID: 11419425
    [Abstract] [Full Text] [Related]

  • 15. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
    Sabatine MS, Jang IK.
    Am J Med; 2000 Aug 15; 109(3):224-37. PubMed ID: 10974186
    [Abstract] [Full Text] [Related]

  • 16. Glycoprotein IIb-IIIa antagonists in non-ST elevation acute coronary syndromes and percutaneous interventions: from pharmacology to individual patient's therapy: part 1: the evidence of benefit.
    Zimarino M, De Caterina R.
    J Cardiovasc Pharmacol; 2004 Mar 15; 43(3):325-32. PubMed ID: 15076214
    [Abstract] [Full Text] [Related]

  • 17. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA.
    Eur Heart J; 1998 Apr 15; 19 Suppl D():D10-21. PubMed ID: 9597518
    [Abstract] [Full Text] [Related]

  • 18. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
    Hobbach HP, Schuster P.
    Z Kardiol; 2003 Mar 15; 92(3):213-8. PubMed ID: 12658467
    [Abstract] [Full Text] [Related]

  • 19. GP IIb/IIIa inhibitors in coronary artery disease management: what the latest trials tell us.
    Chew DP, Moliterno DJ.
    Cleve Clin J Med; 2001 Dec 15; 68(12):1017-23. PubMed ID: 11765119
    [Abstract] [Full Text] [Related]

  • 20. IIb's are not IIb's.
    Kereiakes DJ, Runyon JP, Broderick TM, Shimshak TM.
    Am J Cardiol; 2000 Apr 27; 85(8A):23C-31C. PubMed ID: 10793177
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.